Why WA may have to shift its focus to making ambulance ramping safer
That figure breaks all previous records — even those set during the height of COVID.
It goes without saying, that's a big problem.
Those ambulance crews aren't on the road answering other calls, and patients are receiving less-than-ideal care.
In the grand scheme of the behemoth that is Western Australia's health system, it is also a symptom of much deeper problems, according to experts.
The first problem is the state does not have enough hospital beds to meet demand.
On the most recent data (up to mid-2023) Western Australia had the second-lowest rate of hospital beds based on population out of all states and territories.
For comparison, if WA had the same ratio of beds per person as the highest state – Tasmania – it would have had an extra 1,500 or so places.
'We've delivered over 900 beds to the hospital system since 2021, we've increased staff by 30 per cent and we're looking at innovative ways that we can deliver care,' Health Minister Meredith Hammat said on Friday.
But the state still needed 'at least 1,000 more beds', according to the Australian Medical Association.
'At the end of the day, we need more beds. We need more capacity in our health system. It really can't get any simpler than that,' WA President Kyle Hoath said.
Those beds can take a long time to build and bring online – not the solution you want in the middle of an immediate crisis.
There's also the problem, the government says, of too many beds being taken up by people who could be in aged care.
But solving the problems in that sector is not quick or straightforward, either.
Dr Hoath's solution was to look to private hospitals and medi-hotels, where he said there was spare capacity.
'There are beds there that could be used as hospital beds and we need to take advantage of that,' he said.
Ms Hammat wasn't giving away whether she thought that was a good idea though.
It was a similar answer she gave to almost every question – repeating that phrase 17 times in about 14 minutes while offering no new ideas on how to tackle the problem.
The second problem ramping reveals, according to Dr Hoath, is that the hospital system does not have the capacity to handle the increased load of serious illness presenting to emergency departments.
In responding to the grim total, Ms Hammat pointed to the government's efforts to divert people away from hospitals as a success.
The minister singled out the Virtual Emergency Department program, which connects patients with doctors before they reach hospital.
She said a trial of the program enabled 74 per cent of people who called for an ambulance to receive care without going to an emergency department.
That could help explain why the number of semi-urgent and non-urgent cases in WA's emergency departments reduced by about 10 per cent between 2020-21 and 2023-24.
But it was not enough to offset a 15 per cent increase in the two most serious categories – resuscitation and emergency – over that same period.
'Where people may have presented with severe diabetes in the past, they're now presenting in renal failure and needing a transplant,' Dr Hoath said.
'People are more unwell because they're not getting the care they need at the right time.'
That's a tricky problem to solve but would likely be helped in the long run by increased bulk billing rates – which the federal government could face an uphill battle to do – and more care in the community, rather than in hospitals.
But that's also much easier said than done.
The opposition was squeezing the terrible report card on WA's health system for every political point it could on Friday.
'Don't build race tracks, don't build movie studios, don't do those other things,' leader Basil Zempilas said.
'My strongest advice for the premier would be: make it your number-one focus.
'That means every day when you get up, and you drive up from Kwinana, don't think about other projects.
'Think about health. Make that your job, your responsibility, until the people of Western Australia know that ambulance ramping is on the way down.'
It's an idea many would challenge. Governments can, and do, handle doing many things at the same time, while prioritising some issues over others.
But shadow health spokesperson Libby Mettam made a point many would agree with.
'How is it in a state as wealthy as Western Australia that we have such a crumbling health system?' she asked.
The answer is there's no simple answer.
Building a health system which can meet the growing demands of a rapidly aging population is one of the most wicked problems governments across Australia face.
Add in a worse-than-usual flu season with low vaccination rates and there's little surprise hospitals are so full.
Earlier last week, having investigated the deaths of three people who passed away while ramped, a South Australian Coroner called on that state's government to acknowledge ramping is 'a reality that all modern healthcare systems encounter'.
'While efforts to reduce the levels of ramping remain extremely important, efforts must also be made to make the process of ramping safer for those patients who will inevitably experience it,' Acting Deputy State Coroner Ian White concluded.
That might be an unpalatable answer for many.
But if growing demand for healthcare continues to massively outstrip government's ability to meet it, that focus might make the best of a bad situation until the effects of wider reforms start to be felt.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
2 hours ago
- News.com.au
Valentina is the first Australian ever with extremely rare genetic condition
Valentina's face lights up when customers enter her mum and dad's sandwich shop in Sydney's Little Italy. 'We call her the welcoming party. She sits there and smiles at people when they come in. She's done that from day one,' says Valentina's mum Sara. You would never know that every day is a struggle for the 14-month-old who has a condition so rare she is the only Australian in history to receive her diagnosis. Less than 200 people on the planet have ever experienced what she is experiencing — a rare genetic abnormality that was the result of the ever rarer circumstance that both her parents carried the same gene. 'That we would both have it and marry each other and have a child was so unlikely,' Sara says. 'There are 200 of these cases, ever in the world. None in Australia. Usually these people are cousins who have the same gene but that's not the case with us. So it's pretty crazy that this has manifested this way.' Valentina has Hyaline Fibromatosis Sydrome, characterised by severe pain with movement and progressive joint contractures. 'She can't stretch her legs or lift her arms above her head,' Sara tells 'It manifests through gut problems too, where you don't hold in the nutrients from foods, face rashes, things like that.' Getting a diagnosis was a miracle in itself, one that started the day after she was born when Sara's instincts told her something was not right. 'It was the second day after coming out of the c-section. I noticed straight away,' she says. 'I am an overthinker, but everyone was like, 'you're trying to find a problem'. But I knew.' Sara says she was 'robbed' of the first four months of Valentina's life trying to get somebody to listen and acknowledge what she knew deep down. 'I went to a check-up with the community nurse after we left hospital and she agreed that she wasn't moving her arms properly. 'We went for a brain scan and it came up as nothing. Her brain is unaffected.' Despite receiving no diagnosis, Sara started taking Valentina to physio from four weeks old. 'I kept going as if something was wrong even though nobody would confirm it. A pediatrician at three months said 'yep, actually her legs are concerning me the most'. Her legs had gone from completely normal to completely contracted. 'We went to the hospital on October 9 last year and they were searching and searching and searching for the gene that was causing the problem. 'It is very very difficult to find because our mutations of this gene have never been reported.' Valentina became a research patient. Her DNA and genetics were sent to researchers in Perth who found the gene and checked it against Sara and her husband Dom. 'They confirmed we both had these mutations. Initially they told us we might never have a diagnosis. They said it could take five weeks or five years but we got it in three months.' That's step one. The next step is a bit unknown. 'For us, we're writing the book for this,' Sara says. 'So we don't know the prognosis. We are absolutely writing the book. 'All I know is that she's getting better. There are situations where the contractions can stabilise so we're hoping that's what happens. We don't know the outcome after that. She is on her feet standing with splints. 'When people ask me, 'is she going to walk?'. I say 'I don't know, your guess is as good as mine'. There are no case studies for us to follow, we take it day by day really.' The family's sandwich shop, Dom Panino, sits on the corner of Marion and Edith streets in Leichardt, the iconic inner west suburb of Sydney best known for its Italian food and culture. It started as a food truck at Breakfast Point before Dom and Sara found the perfect location — a restaurant Dom used to frequent when he was younger with his family. Valentina sits inside the entrance now welcoming customers with a smile. In a heartwarming video posted to the pair's social media pages, customers rallied around the family. 'This panino is for Valentina and Jeans for Genes,' customers recited on a day that raised more than $24,000 for the Children's Medical Research Institute. Jeans for Genes Day, which takes place this Thursday, August 7, is about finding treatments for the one-in-20 Aussie children like Valentina who live with conditions like cancer, cystic fibrosis and other devastating genetic diseases. The cause helps raise money to keep labs open, continue with life-changing science and save lives. Sara says raising funds and speaking up for her little girl are an important way of helping her move through the grief. 'This can't be for nothing,' she says. 'I can't just sit here and not tell the world about it. I want Valentina to know that she's so incredible, and so brave and so strong and she's going to live a normal life. I want to make a difference.'

News.com.au
4 hours ago
- News.com.au
MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks
MoneyTalks is Stockhead's drill down into what stocks investors are looking at right now. We tap our list of experts to hear what's hot, their top picks and what they're looking out for. Today we hear from Australia's Summit Biotech Fund manager Reece O'Connell. With experience trading through multiple economic and market cycles, Reece O'Connell has developed a long-term investment approach focused on preserving and growing capital. In a career that has taken him from Perth to London and back again, he has worked closely with high-net-worth and wholesale investors, tailoring strategies to meet their objectives while navigating changing market conditions. At Summit Biotech Fund (SBF) he aims to provide long-term capital growth by investing in a portfolio of life science companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices and equipment, medical data, information technology (e-health), and robotics. And in some good news for the fund, a rotation back into the healthcare sector appears to be gaining momentum with the S&P ASX 200 Health Care index rising 9.05% in July. "The healthcare sector has been the worst performing sector for two years and there's great positioning in quality healthcare names before the sector turns," he said. "We see these sector rotations every three to five years and I believe the ASX healthcare sector represents good value and plenty of upside in quality names with strong management." Here's three companies Summit Biotech Fund has invested in and why. Arovella Therapeutics (ASX:ALA) SBF is a major shareholder in Arovella, which is developing a next-generation cell therapy platform based on invariant Natural Killer T (iNKT) cells engineered with Chimeric Antigen Receptors (CARs) to target specific cancer antigens. Unlike traditional CAR-T therapies, Arovella's approach uses healthy donor cells to create off-the-shelf treatments, which reduces cost, complexity and time to treatment — the major issues currently faced by CAR-T companies. Arovella's lead candidate, ALA-101, targets CD19-positive blood cancers, and its pipeline encompasses therapy development for solid tumours such as gastric and pancreatic cancers. O'Connell reckons Arovella is in a hot area of cancer research. Nasdaq-listed MiNK Therapeutics recently soared following publication of a case report in the peer-reviewed Oncogene journal, detailing a patient with advanced, treatment-refractory testicular cancer who achieved complete remission after receiving its lead product iNKT Agentâ€'797, in combination with the immune checkpoint inhibitor nivolumab. "Arovella presents an opportunity in a rapidly growing sector, with a differentiated platform and strong early-stage clinical momentum," O'Connell said. "The company is the only ASX-listed biotech delving into CAR-iNKT therapies and one of only a handful globally." He said Arovella was well funded, finishing Q4 FY25 with cash of $20.9 million, which should fund the company through to completion of patient enrolment for its phase I clinical trial for ALA-101 n non-Hodgkin's lymphoma and leukaemia patients exhibiting the CD-19 biomarker – the target its CAR-iNKT cells recognise. The funding will also support the advancement of the company's solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). "ALA presents a highly compelling investment opportunity over the next six to 12 months, given the competitive landscape and the deals being struck for allogeneic assets and platforms," O'Connell added. SBF is a significant shareholder in Tryptamine, a clinical-stage biopharmaceutical company developing next-generation psychedelic medicines for neuropsychiatric conditions. Its lead program, TRP-8803, is a proprietary, IV-delivered formulation of psilocybin designed to provide more precise dosing and improved patient tolerability compared to oral psychedelic treatments. Phase 1b trials have already shown the drug to be safe and well tolerated in obese and non-obese participants. The company recently kicked off a world-first psilocin trial with TRP-8803 targeting Binge Eating Disorder (BED). The study, run in collaboration with Swinburne, will assess TRP-8803 when administered with psychotherapy with the goal to evaluate safety, feasibility and efficacy in adults diagnosed with BED. For O'Connell when analysing a biotech it as much about who is running the company as it is about the science. "One of the most important investment themes I always look for is a material monetary investment by directors in a company," he said. "Too many small ASX-listed companies have boards that aren't truly aligned with shareholders. "The number one way to be aligned is to have directors putting in their hard-earned cash like us. In this case, TYP ticks all the boxes.' He said directors, management,and major shareholders were collectively invested for more than $9m, with CEO Jason Carroll personally contributing more than $1 million. Carroll's 30-year career in big pharma includes two decades at Johnson & Johnson, where he led the strategy that doubled US sales of Remicade — a blockbuster IBD drug that ultimately reached US$10bn in annual global sales. O'Connell said other board members brought similar firepower. Executive director Chris Ntoumenopoulos was involved in the growth of Race Oncology (ASX:RAC) from $10m to north of $200m, founded former ASX-listed ResApp Health, which was acquired by Pfizer for ~$200m, and has helped double Island Pharmaceuticals' (ASX:ILA) value since joining its board. As part of the last raise experienced biotech investor Dr Daniel Tillett joined the Tryptamine board as a non-executive director and became a cornerstone investor. Tillet also cornerstoned a raise in Race Oncology in its early days and now leads it as CEO and managing director. Recent clinical progress provides Tryptamine with valuable proprietary data as its seek to advance the use of TRP-8803 in patient-specific indications. "With a differentiated psychedelic platform, directors heavily invested alongside shareholders, and multiple catalysts on the horizon, Tryptamine is emerging as one of the more compelling plays in the sector," O'Connell said. SBF also holds a strong position in NeuroScientific, which O'Connell said was positioning itself as a serious player in the fast-growing field of stem cell therapies for immune-mediated diseases, underpinned by its recently acquired StemSmart platform. The patented mesenchymal stromal cell (MSC) therapy has shown strong early results including a 53% remission rate in a phase II trial for refractory Crohn's disease and outperforming Humira, the long-time anti-inflammatory drug used as a standard of care. It also showed high response rates in a phase I trial for steroid-refractory Graft-versus-Host Disease (GvHD). "With the global markets for Crohn's and GvHD forecast to reach US$25 billion combined by 2035, StemSmart is tapping into significant unmet needs," O'Connell said. He also sees validation from the sector's leader Mesoblast (ASX:MSB), which recently secured US Food and Drug Administration (FDA) approval for its MSC product and now commands a $3.1bn market cap. He said by comparison, Neuroscientific trades at just ~23 cents but carries a midpoint valuation of 60 cents, representing around 161% upside based on a probability-adjusted DCF model assuming modest success rates and future partnerships. This assumes modest 20% success rates, 25% market penetration in Crohn's and potential partnerships with big pharma to fund late-stage trials. With a Special Access Program about to generate real-world data, plans to initiate Phase II trials in 18–24 months, and expansion into additional inflammatory and lung diseases, StemSmart offers a scalable pipeline. "For investors looking at the MSC space NSB could be an early-stage, high-upside opportunity positioned to follow Mesoblast's trajectory as the market matures," he said. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Disclosure: Summit Biotech Fund held shares in Arovella, Tryptamine Therapeutics and NeuroScientific Biopharmaceuticals at the time of writing this article.

ABC News
4 hours ago
- ABC News
Family grateful for end-of-life care at Rockhampton's Fitzroy Community Hospice
Struggling to breathe, battling a staphylococcus infection and suffering from other age-related illnesses, Neil Robinson's family knew he was nearing the end of his life. His family did not want the 85-year-old to die in hospital, but knew bringing him home could be overwhelming and complicated. "His ailments were complex, and it was very daunting to think about caring for him ourselves," Neil's daughter-in-law Toni Robinson said. A friend suggested hospice care, and it ended up being the solution Neil's family was looking for. "My friend's father was cared for at a hospice, and it was such a comfort to his family," she said. Neil spent his last week at the Fitzroy Community Hospice, the only end-of-life care option outside hospitals or aged care homes between Gympie and Townsville, a stretch of nearly 1,000 kilometres. The community not-for-profit hospice opened its doors in June 2024 to provide better end-of-life care in central Queensland. The second stage of the project opened last month to expand its capacity. The new rooms have more space for families, which means people coming from outside the area to be with loved ones have somewhere to stay. "Some people have confused us with aged care, but those we care for are referred to us through medical practitioners and nurse practitioners," chief executive officer Beth Thomas said. Funding is provided through an agreement with Queensland Health for several public beds and private health insurers, as well as ongoing fundraising. Ms Thomas said the organisation's executives worked with local GPs and the community to get the word out about the specifics of end-of-life care. "It's about taking the burden of care from families and hospitals," Ms Thomas said. "A big difference from a hospital is that we don't have fixed visiting hours. Family members and pets can come and visit any time. "It is meant to be a soothing and calming environment with no bells and whistles and bustling that the hospital has." Allison Leech, a nursing teacher at CQ University and former director of nursing at Toowoomba Hospice, believed more palliative care options were needed in regional areas as it eases the burden for both local health care systems and families. "Many Australians want to die at home, but it's not always possible. So this becomes a home-like environment, and patients and families can do things on their own terms." Fitzroy Hospice clinical nurse Megan Anderson saw the hospice as a place to create memories. "It is holistic and we see the family as a key part of patient care," she said. A Queensland Health spokesperson said hospice care was a critical part of the health care system, providing funding to some non-government organisations for palliative care services. "Our palliative and end-of-life care strategy includes $171 million to fund more palliative care services and boost the workforce across the state," the spokesperson said. Neil died in January this year after spending a week at the hospice. Ms Robinson said the week was spent sitting at Neil's side with Hope, the family dog, resting her head in Neil's hand. She said it was a "peaceful passing for Neil" and a comforting experience for the family. "The staff provided us with everything we needed to know so we understood the dying process," Ms Robinson said. "It was the next best thing to caring for Neil at home."